创新药龙头重磅业绩利好！百济神州2月26日发布2025年度业绩快报，全年营收382.05亿元，同比增 40.4%；归母净利润14.22亿元，实现扭亏为盈。 值得一提的是，这是这家创新药龙头公司首次实现年度盈利，也是中国创新药企全球化发展的重要里程 碑。 公告显示，百济神州业绩增长得益于核心产品放量，2025年百悦泽全球销售额280.67亿元，同比增长 48.8%。此外，公司多款候选药物进入临床关键阶段，百悦达在中国获批上市，BGB-B2033获FDA快速 通道资格认定。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏创新药机遇，借道ETF效率更高！ 投纯正创新药，认准T+0利器——港股通创新药ETF（520880）及其场外联接基金（025221），100%布 局创新药研发类公司，前十大权重股占比超七成，龙头属性突出。 降低波动 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- ...

2月26日晚间，百济神州-U（SH688235，股价263.44元，市值4058.76亿元）发布2025年度业绩快报，公司全年实现营业总收入382.05亿元，同比增长 40.4%；归属于母公司所有者的净利润14.22亿元，较上年同期的净亏损49.78亿元实现扭亏为盈。 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 38,204,601 | 27,213,955 | 40.4 | | 其中:产品收入 | 37,769,870 | 26,993,842 | 39.9 | | 营业利润 | 2,562,102 | -4.161.996 | 不适用 | | 利润总额 | 2,558,155 | -4,162,650 | 不适用 | | 归属于母公司所有者的 | 1,422,185 | -4.978.287 | 不适用 | | 净利润 | | | | | 归属于母公司所有者的 扣除非经常性损益的净 | 1,381,283 | -5,379,293 | 不适用 | | 利润 | | | | 图片来源：百济神州-U公告 《每日经济新 ...

Core Viewpoint - BeiGene has rapidly commercialized its product, Baiyueda, just eight days after receiving approval, benefiting adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma in China [1] Group 1 - BeiGene leverages its comprehensive capabilities in research, production, and commercialization to achieve swift market entry [1] - The product is now available for clinical use, indicating a quick transition from approval to patient access [1]

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical sector, with the overall performance of the Shenwan Pharmaceutical and Biological Index increasing by 7.8% during the week, outperforming the Shanghai Composite Index which rose by 3.82% [2][3]. Core Insights - The pharmaceutical sector's overall valuation stands at 30.6 times earnings, ranking 10th among 31 Shenwan primary industries [5]. - The report highlights significant developments in the long-term care insurance system transitioning from pilot programs to full establishment during the 14th Five-Year Plan, with coverage reaching nearly 300 million people and fund expenditures exceeding 100 billion yuan by the end of 2025 [11]. - Notable advancements in drug commercialization include the launch of Novo Nordisk's oral GLP-1 weight loss drug Wegovy in the U.S., with monthly costs ranging from $149 to $299 for self-paying patients [13][14]. - Moderna has submitted a New Drug Application (NDA) for its seasonal flu vaccine mRNA-1010, showing promising efficacy results in clinical trials [15]. - Arrowhead has reported positive mid-stage results for its RNAi therapies ARO-INHBE and ARO-ALK7, demonstrating significant reductions in visceral and liver fat [16][17]. - GSK's hepatitis B drug Bepirovirsen has shown statistically significant functional cure rates in its Phase III trials [18]. - Recent approvals for innovative drugs in China include BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which addresses familial chylomicronemia syndrome [19][21]. Summary by Sections Market Performance - The Shenwan Pharmaceutical and Biological Index increased by 7.8%, ranking 6th among 31 Shenwan primary industries [2][3]. - Various sub-sectors showed positive growth, with medical devices and medical outsourcing leading with increases of 10.8% and 11.1%, respectively [5]. Industry Dynamics - The long-term care insurance system is set to expand significantly, with a focus on providing care for the elderly and disabled [11][12]. - The report emphasizes the importance of innovation in drug development, particularly in RNAi therapies and small nucleic acid drugs, which are gaining traction in clinical settings [16][18]. Company Developments - Significant partnerships and collaborations are highlighted, such as the $8.88 billion research collaboration between Insilico Medicine and Servier focusing on oncology [20]. - The report notes the successful commercialization of several new drugs, including BeiGene's and Sanofi's recent approvals, which are expected to impact market dynamics positively [19][21]. - The establishment of new companies and subsidiaries, such as the brain-computer interface subsidiary by Xinwei Medical, indicates a strategic shift towards innovative technologies in healthcare [22].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

Group 1 - Gold stocks experienced a general decline, with Jintian falling by 4.5% and Harmony Gold decreasing by 3.6% [1] - Ventyx Biosciences saw a significant increase of 51.0% following Eli Lilly's announcement of a planned acquisition for over $1 billion [1] - Mobileye rose by 17.2% after officially announcing a $900 million acquisition of the robotics company Mentee [1] Group 2 - BeiGene's stock increased by 4.2% after receiving market approval in China for its new BCL2 inhibitor, Baiyueda [1]

Market Overview - After a rapid rise, the global stock market is losing momentum, with signs of "overheating" [2][21] - The Dow futures are up 0.04%, while S&P 500 futures are down 0.08% and Nasdaq futures are down 0.24% [3][21] - The ADP report indicates a rebound in December employment, with private sector adding 41,000 jobs, below the market expectation of 47,000 [22] Geopolitical Factors - President Trump's threats regarding the potential acquisition of Greenland have heightened market tensions [22] - The U.S. military's actions leading to the capture of Venezuelan leader Maduro have drawn global market attention [22][24] - Greenland and Denmark have reiterated that the territory is not up for grabs, emphasizing local sovereignty [22] Economic Indicators - The upcoming U.S. labor market and business activity data are expected to test the sustainability of current market optimism [24] - The Bloomberg Dollar Index has continued its previous day's gains, with the dollar index slightly rising to 98.63 [26] - The market anticipates two more interest rate cuts from the Federal Reserve this year, which may weigh on the dollar [26] Commodity Market - Precious metals have weakened, with silver dropping below $80 and gold ending a three-day rise [23] - Oil prices have declined, with Brent crude down 0.8% to just above $60 [27] Corporate Highlights - Gold and silver stocks have seen pre-market declines, with notable drops including Kinross Gold down 1.71% and Harmony Gold down 3.18% [28] - Mobileye shares surged over 10% following the announcement of a $900 million acquisition of robotics company Mentee [30] - Ventyx Biosciences stock soared 70% as Eli Lilly plans to acquire the company for over $1 billion [32]